Table 3 COPD severity among new users aged 40 years or older with COPD at the index date, by study medication and by data source.

From: No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study

COPD severity categories, N (%)a

PHARMO Overall

PHARMO-GP

Danish population registers

Olodaterol

(N = 1,386)

Indacaterol

(N = 1,841)

Olodaterol

(N = 372)

Indacaterol

(N = 636)

Olodaterol

(N = 1,712)

Indacaterol

(N = 6,406)

N total

662

648

276

405

1,115

1,835

Mildb

23 (3.5)

63 (9.7)

17 (6.2)

53 (13.1)

67 (6.0)

390 (21.3)

Moderatec

255 (38.5)

242 (37.3)

144 (52.2)

180 (44.4)

300 (26.9)

503 (27.4)

Severed

264 (39.9)

226 (34.9)

69 (25.0)

94 (23.2)

572 (51.3)

779 (42.5)

At least one hospitalization for COPD exacerbation in prior year

192 (72.7)

177 (78.3)

35 (50.7)

55 (58.5)

356 (62.2)

450 (57.8)

At least two COPD exacerbations without hospitalization, where COPD exacerbation is defined by any of the following:

98 (37.1)

47 (20.8)

28 (40.6)

20 (21.3)

392 (68.5)

490 (62.9)

A diagnosis of COPD exacerbation without hospitalization

11 (11.2)

6 (12.8)

11 (39.3)

6 (30.0)

32 (8.2)

40 (8.2)

A course of antibiotics for respiratory tract infections

75 (76.5)

30 (63.8)

18 (64.3)

10 (50.0)

353 (90.1)

453 (92.4)

A course of systemic glucocorticosteroids for COPD exacerbation

84 (85.7)

37 (78.7)

21 (75.0)

14 (70.0)

291 (74.2)

323 (65.9)

Very severee

120 (18.1)

117 (18.1)

46 (16.7)

78 (19.3)

176 (15.8)

163 (8.9)

Dispensed oxygen therapy in prior year

NA

NA

NA

NA

32 (18.2)

17 (10.4)

Dispensed nebulizer therapy in prior year

38 (31.7)

14 (12.0)

6 (13.0)

2 (2.6)

45 (25.6)

16 (9.8)

Diagnosis of emphysema at any time before index date

83 (69.2)

101 (86.3)

39 (84.8)

73 (93.6)

116 (65.9)

135 (82.8)

  1. COPD = chronic obstructive pulmonary disease; LABA = inhaled long-acting beta2-agonist; NA = not available; PHARMO = PHARMO Database Network; PHARMO-GP = PHARMO General Practitioner Database.
  2. aSeverity categories were mutually exclusive and patients that fulfill criteria for more than one category were classified as being in the most severe category. The proportion of patients in each COPD severity category was calculated over the total number of new users aged 40 years or older with COPD at the index date. For indented subcategories of the COPD severity groups, the proportion of patients was calculated over the number of patients in the non-indented category or subcategory.
  3. bPatients were classified in this category when they did not fulfill criteria for very severe, severe, or moderate.
  4. cAt least two prescriptions/dispensings of the same COPD drug class with a maximum interval of 6 months in the 12 months before index date.
  5. dPatients with at least one of the listed criteria for severe in the prior year.
  6. ePatients with at least one of the listed criteria for very severe.
Back to article page